Form 4: Adverum Biotechnologies Director Acquires Stock Options
SEC Form 4 Filing
Mark L. Lupher, Jr., a director of Adverum Biotechnologies, acquired stock options exercisable for 10,520 shares of common stock.
Summary
- Mark L. Lupher, Jr., a director of Adverum Biotechnologies, Inc., filed a Form 4 on June 20, 2024, regarding changes in beneficial ownership.
- On June 17, 2024, Lupher acquired stock options for 10,520 shares of Adverum's common stock at an exercise price of $7.32.
- These options vest on the earlier of June 17, 2025, or the 2025 annual meeting of stockholders, subject to accelerated vesting upon a change of control and continued service with the Issuer on the vesting date.
- Following the transaction, Lupher directly owns 10,520 derivative securities.
- Lupher also granted a Power of Attorney to certain officers of Adverum Biotechnologies, Inc. to execute and file Forms 3, 4, and 5 on his behalf.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in the biotechnology industry. Investors often monitor these filings for signals about management's confidence in the company.
Comparison to Industry Standards
- Stock option grants to directors are a common form of compensation in the biotechnology industry.
- The vesting schedule and terms are fairly standard compared to other companies in the sector.
- Comparable companies such as BioMarin Pharmaceutical and Sarepta Therapeutics also regularly disclose similar transactions by their directors and officers.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.
Key Dates
| Date | Description |
|---|---|
| 2024-03-16 | Date of Power of Attorney execution. |
| 2024-06-17 | Date of stock option acquisition. |
| 2024-06-17 | Options vest on the earlier of this date in 2025 or the 2025 annual meeting of stockholders. |
| 2024-06-20 | Date of Form 4 filing. |
| 2034-06-16 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.